Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(21 sites) United States
The Kirklin Clinic of University of Alabama Birmingham Hospital, Birmingham, Alabama University of California San Diego, La Jolla, California Norris Comprehensive Cancer Center, Los Angeles, California University of California Irvine Medical Center, Orange, California University of Colorado Hospital - Anschutz Medical Campus, Aurora, Colorado Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia Moffitt Cancer Center, Tampa, Florida The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland University of Michigan Rogel Cancer Center, Ann Arbor, Michigan Barbara Ann Karmanos Cancer Institute, Detroit, Michigan Washington University in St. Louis, St Louis, Missouri Memorial Sloan Kettering Cancer Center - New York, New York, New York Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas DHR Health Institute for Research & Development, Edinburg, Texas University of Texas MD Anderson Cancer Center, Houston, Texas University of Texas Health Science Center - San Antonio, San Antonio, Texas Virginia Mason Medical Center, Seattle, Washington Summit Cancer Centers - North Spokane, Spokane, Washington Froedtert and Medical College of Wisconsin, Milwaukee, Wisconsin